PCPing Chen

Ping Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ping Chen has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pleiotrophin modulates cell proliferation, prostate smooth muscle contraction and fibrosis in hyperplastic prostate

    by Jiang Liu, Jiuming Fan, Huan Liu, Mingzhe Chen, Xun Fu, Yiqiao Zhao, Muyang Cheng, Yuming Guo, Yan Li, Jianmin Liu, et al.

    Benign prostatic hyperplasia (BPH) is a common disease afflicting elderly males all over the world. The existing scientific research still has not completely clarified its etiology. Pleiotrophin (PTN) is a developmental regulatory protein involved in various biological processes. This study aimed to elucidate the expression, biological function, and underlying mechanism of PTN in the onset and progression of BPH. Human prostate tissues, cell lines, rat models and PTN-knockout mice models were utilized. PTN knockdown, PTN overexpression, and estradiol cell models were established. The qRT-PCR, Western Blot, flow cytometry, CCK-8 assay, collagen gel contraction assay, co-immunoprecipitation, immunofluorescence, H&E, Masson’s trichrome, immunohistochemical staining, TUNEL assay and tissue micro-array analysis were performed during in vivo and in vitro experiments. Our current data validated that PTN is localized in stroma and epithelium of the prostate, with stronger expression in BPH tissues. Functionally, silenced PTN promoted cell apoptosis while it inhibited cell proliferation, cell contraction and fibrosis. Consistently, overexpression of PTN suppressed cell apoptosis, and facilitated cell proliferation, cell contraction, as well as fibrosis. More importantly, AKT phosphorylation and RhoA/ROCK1/2 axis were confirmed to be involved in the regulation of prostate biological processes by PTN. Moreover, estradiol treatment could enhance PTN expression and modulate downstream biological process. Also, PTN expression was correlated with prostate volume (PV), fPSA and the ratio of fPSA/tPSA. Finally, recombinant PTN induced prostatic hyperplasia in rats, PTN knockout suppressed BPH in mice, and estradiol treatment upregulated PTN expression. These results further confirm the crucial role of PTN in BPH onset and progression. Our current study demonstrates that PTN is of significance in the onset and development of BPH and may be a new target for the treatment of BPH.


  • Zero-Intrarenal Pressure Percutaneous Nephrolithotomy for One-Stage Treatment of Non-Acute Infectious Calculous Pyonephrosis: A Strategy to Avert Sepsis

    by Ying-Tong Zuo, Tong-Zu Liu, Bing Li, Sheng Li, Yong-Zhi Wang, Ping Chen, Xing-Huan Wang, Zhong-Hua Wu

    Purpose: To evaluate the efficacy and safety of a novel zero-intrarenal pressure (IRP) percutaneous nephrolithotomy (PCNL) technique for one-stage treatment of non-acute infectious calculous pyonephrosis. Patients and Methods: This retrospective study analyzed 12 patients (4 males, 8 females; mean age 56.4 years) who underwent zero-IRP PCNL. The technique utilized a double-sheath vacuum suction system, with the outer sheath allowing for gravity irrigation and the inner sheath facilitating continuous suction. Keeping the height of gravity perfusion at the level of the kidney inherently prevented high IRP and achieved zero-IRP PCNL, even when stone fragments obstructed the suction channel. Results: The procedure demonstrated a high initial stone-free rate of 75%, improving to 91.7% after 1 month. The average operative time was 50.7 minutes. The mean hemoglobin drop was 6.1 g/L, managed without transfusions. Complications were minimal, with low-grade fever in two patients. No significant intraoperative or postoperative complications, such as sepsis, were noted. Conclusions: The zero-IRP PCNL technique, characterized by its double-sheath vacuum suction system and zero-pressure gravity perfusion, shows promise in safely and effectively managing non-acute infectious calculous pyonephrosis. Preliminary results are encouraging, but further research with larger sample sizes is essential for broader clinical validation.


  • Open Access

    The Emerging Role of Cell Adhesion Molecules on Benign Prostatic Hyperplasia

    by Jiang Liu, Junchao Zhang, Xun Fu, Shu Yang, Yan Li, Jianmin Liu, Michael E. DiSanto, Ping Chen, Xinhua Zhang

    Benign prostatic hyperplasia (BPH) is a common disease in elderly men. It is characterized by prostatic enlargement and urethral compression and often causes lower urinary tract symptoms (LUTs) such as urinary frequency, urgency, and nocturia. Existing studies have shown that the pathological process of prostate hyperplasia is mainly related to the imbalance of cell proliferation and apoptosis, inflammation, epithelial–mesenchymal transition (EMT), and growth factors. However, the exact molecular mechanisms remain incompletely elucidated. Cell adhesion molecules (CAMs) are a group of cell surface proteins that mediate cell–cell adhesion and cell migration. Modulating adhesion molecule expression can regulate cell proliferation, apoptosis, EMT, and fibrotic processes, engaged in the development of prostatic hyperplasia. In this review, we went over the important roles and molecular mechanisms of cell adhesion molecules (mainly integrins and cadherins) in both physiological and pathological processes. We also analyzed the mechanisms of CAMs in prostate hyperplasia and explored the potential value of targeting CAMs as a therapeutic strategy for BPH.


  • Open Access

    Changes in the Expression and Functional Activities of C-X-C Motif Chemokine Ligand 13 (CXCL13) in Hyperplastic Prostate

    by Daoquan Liu, Mingzhou Li, Xun Fu, Shu Yang, Zhen Wang, Jianmin Liu, Yan Li, Yongying Zhou, Pengfei Ren, Yuhang Guo, et al.

    Background: C-X-C motif chemokine ligand 13 (CXCL13), a member of the CXC subtype in chemokine superfamily, affects numerous biological processes of various types of cells and the progress of a great number of clinical diseases. The purpose of the current study was to reveal the internal mechanism between CXCL13 and benign prostatic hyperplasia (BPH). Methods: Human serum, prostate tissues and human prostate cell lines (BPH-1, WPMY-1) were utilized. The effect of recombinant human CXCL13 (rHuCXCL13) protein and the influences of the knockdown/overexpression of CXCL13 on two cell lines were studied. Rescue experiments by anti-CXCR5 were also conducted. In vivo, rHuCXCL13 was injected into the ventral prostate of rats. Additionally, a tissue microarray of hyperplastic prostate tissues was constructed to analyze the correlations between CXCL13 and clinical parameters. Results: CXCL13 was highly expressed in the prostate tissues and upregulated in the BPH group. It was observed that CXCL13 modulated cell proliferation, apoptosis, and the epithelial–mesenchymal transition (EMT) through CXCR5 via AKT and the ERK1/2 pathway in BPH-1, while it contributed to inflammation and fibrosis through CXCR5 via the STAT3 pathway in WPMY-1. In vivo, rHuCXCL13 induced the development of rat BPH. Additionally, CXCL13 was positively correlated with the prostate volume and total prostate specific antigen. Conclusions: Our novel data demonstrated that CXCL13 modulated cell proliferation, cell cycle, the EMT of epithelial cells, and induced the fibrosis of prostatic stromal cells via a variety of inflammatory factors, suggesting that CXCL13 might be rediscovered as a potential therapeutic target for the treatment of BPH.


  • Top Cited Papers
    Open Access

    Causal relationship between obesity, lifestyle factors and risk of benign prostatic hyperplasia: a univariable and multivariable Mendelian randomization study

    by Yong-Bo Wang, Lan Yang, Yu-Qing Deng, Si-Yu Yan, Li-Sha Luo, Ping Chen, Xian-Tao Zeng

    Background: Obesity (waist circumference, body mass index (BMI)) and lifestyle factors (dietary habits, smoking, alcohol drinking, Sedentary behavior) have been associated with risk of benign prostatic hyperplasia (BPH) in observational studies, but whether these associations are causal is unclear. Methods: We performed a univariable and multivariable Mendelian randomization study to evaluate these associations. Genetic instruments associated with exposures at the genome-wide significance level (P < 5 × 10–8) were selected from corresponding genome-wide associations studies (n = 216,590 to 1,232,091 individuals). Summary-level data for BPH were obtained from the UK Biobank (14,126 cases and 169,762 non-cases) and FinnGen consortium (13,118 cases and 72,799 non-cases). Results from UK Biobank and FinnGen consortium were combined using fixed-effect meta-analysis. Results: The combined odds ratios (ORs) of BPH were 1.24 (95% confidence interval (CI), 1.07–1.43, P = 0.0045), 1.08 (95% CI 1.01–1.17, P = 0.0175), 0.94 (95% CI 0.67–1.30, P = 0.6891), 1.29 (95% CI 0.88–1.89, P = 0.1922), 1.23 (95% CI 0.85–1.78, P = 0.2623), and 1.04 (95% CI 0.76–1.42, P = 0.8165) for one standard deviation (SD) increase in waist circumference, BMI, and relative carbohydrate, fat, protein and sugar intake, 1.05 (95% CI 0.92–1.20, P = 0.4581) for one SD increase in prevalence of smoking initiation, 1.10 (95% CI 0.96–1.26, P = 0.1725) and 0.84 (95% CI 0.69–1.02, P = 0.0741) for one SD increase of log-transformed smoking per day and drinks per week, and 1.31 (95% CI 1.08–1.58, P = 0.0051) for one SD increase in sedentary behavior. Genetically predicted waist circumference (OR = 1.26, 95% CI 1.11–1.43, P = 0.0004) and sedentary behavior (OR = 1.14, 95% CI 1.05–1.23, P = 0.0021) were associated with BPH after the adjustment of BMI. Conclusion: This study supports independent causal roles of high waist circumference, BMI and sedentary behavior in BPH.